1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Professor and Associate Dean for Research
Pharmaceutical Sciences
Phone (405) 271-6593 x47331
Fax (405) -271-7505
Office CPB 309
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 11. Awasthi V, Eeda V. A Catalyst-Free and Scalable Process for Synthesis of Novel MAP4K4 Inhibitor DMX-5804 and its Glyco-Conjugates. Organic Process Research & Development. 2021; 25 : 1658–1663
12. Awasthi V, Sahoo K. Differential oxidative and pro-apoptotic response to an anti-inflammatory agent CLEFMA. BioRxiv . 2021
13. Awwad H O, Hedrick A, Mdzinarishvili A, Houson H, Standifer K, Awasthi V. Modeling traumatic brain injury combined with hemorrhagic shock in rats: Neurological assessment and PET imaging with 18F-fluorodeoxyglucaric acid. . BioRxiv . 2021
14. Lagisetty P, Eeda V, Yadav V R, Nimmo S L, Subramaniam D, Powell D R, Awasthi V. Tumor suppressive activities of solvatochromic 3,3'-azadimethylene dinaphthospiropyran in colon cancer model. Chemical biology & drug design. 2021; 97 : 325-340
15. Sundriyal S, Eeda V, Lagisetty P, Awasthi V. Tubulin inhibitory activity of a novel colchicine-binding compounds based on a dinaphthospiropyranran scaffold. Bioorganic & medicinal chemistry. 2021; 29 : 115874
Grants
- 1. Mechanism of F-18-fluorodeoxyglucarate accrual in myocardial injury. NHLBI. Start Date: 2024. End Date: 2029.
2. Developing PPARγ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.
3. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.
4. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.
5. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.
Awards and Honors
- 1. USPTO. Patent application issued. Date: 2015.
2. Indo-American Society of Nuclear Medicine (IASNM)Outstanding Presidential Award . Date: 2015.
3. Journal of Pharmaceutical Sciences. Article selected as a featured research paper. Date: 2015.
4. OUHSC-College of Pharmacy. USP Convention Voting Delegate. Date: 2014.
5. Robert Glenn Rapp Foundation. Presidential Professor . Date: 2013.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results